Business Wire

Sistemaitalia.it Was Born, a Group of High-quality Small and Medium-sized Italian Enterprises Unite to Show International Players New Business Opportunities

14.5.2020 10:00:00 EEST | Business Wire | Press release

Share

A platform that supports Italian small and medium-sized enterprises to network and dialogue with big players, access large-scale international business opportunities together: this is the core idea of Sistema Italia , a project born from Uberto Canaccini’s idea, entrepreneur and CEO of CEG Elettronica, recently recognized by Forbes among the top 100 successful managers leading top businesses and multinationals. The objective of Sistema Italia, which is already at 1 billion euros, is to reach 3 billion euros in aggregate turnover.

There is strength in numbers

Sistema Italia addresses privates and SMBs, is made up of a group of entrepreneurs active abroad for a long time in sectors such as infrastructure, railway, fashion, Oil & Gas and renewable energies with contacts, relations and world market knowledge. The aim is to facilitate a rapid recovery and tackle national and international markets cohesively. The service is completely free.

From the point of view of foreign markets, large General Contractors, EPC Contractors, buyers and companies in the field of Food and Beverage will see in Sistema Italia a point of strength to invest in the Belpaese and find advantageous collaborations, and a unison of companies capable of generating value.

Thanks to his entrepreneurial experience, over the past twenty years Uberto Canaccini has made CEG Elettronica Industriale an industrial reference point in the global market with 80% of the turnover achieved abroad and a strong internationalization towards markets such as Kazakhstan, South Korea, Russia, the United Arab Emirates and Saudi Arabia.

“Sistema Italia represents an opportunity for foreign companies and operators to return to focus on our Country", Uberto Canaccini comments. "We are ready to face the international market all together, to show the entrepreneurial and creative vein that characterizes us" he adds.

Privates and companies, by signing up, will find analyzes and insights on decrees and procedures to be activated to be compliant with legal obligations when resuming production activities. The companies will have strategic commercial support to create the necessary synergies to be accredited and to win global tenders and orders in the various foreign markets.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

DAG Communication
Francesca Conti
fconti@dagcom.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Collaborates with Chainguard to Strengthen Software Supply Chain Security through BlueVerse™ RightLogic6.8.2026 14:30:00 EEST | Press release

LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic collaboration with Chainguard, the trusted source for open source, to strengthen software supply chain security through BlueVerse™ RightLogic, LTM's cybersecurity assessment and risk assurance framework. The collaboration enables organizations to strengthen security while maintaining the speed and agility required for AI-enabled software development. With BlueVerse RightLogic, LTM combines AI-powered cyber risk assessment with a growing ecosystem of technology partners to help enterprises identify, assess, and remediate cyber exposure while accelerating AI adoption. Chainguard strengthens the BlueVerse RightLogic ecosystem by helping enterprises secure open-source components from the outset, complementing LTM's cybersecurity services to close the gap between AI-speed discovery and enterprise-speed remediation. As AI adoption accelerates, complex software supply chains and growing relian

teamLab Borderless in Tokyo Welcomes Over 4 Million Visitors from more than 185 Countries6.8.2026 14:07:00 EEST | Press release

teamLab Borderless: MORI Building DIGITAL ART MUSEUM (teamLab Borderless) in Tokyo has welcomed over 4 Million visitors as of July 31, 2026, approximately 2 years and 5 months since its opening.*1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806672709/en/ teamLab Borderless: MORI Building DIGITAL ART MUSEUM in Tokyo Welcomes Over 4 Million Visitors from more than 185 Countries These visitors arrived from more than 185 countries and regions. International visitors account for approximately 70% of the total number. Many of these international visitors travel from distant countries and regions, including the United States, Australia, Canada, the United Kingdom and Germany. Among those who visited Japan between February 2024 and June 2026, approximately 1 in every 12 travelers from the United States, and 1 in every 9 travelers from Australia visited teamLab Borderless.*2 teamLab Borderless was selected by the U.S. based int

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 20266.8.2026 14:00:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and will participate in a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under eva

Purina Named as First Publicly Announced NIQ ConnectAI Charter Client6.8.2026 13:45:00 EEST | Press release

NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today named Purina as the first publicly announced client in its ConnectAI Charter Program. The announcement follows NIQ’s launch of the program with five global organizations across personal care, pet care, beauty and beverages, with additional client announcements and case studies expected as engagements advance. Through ConnectAI, NIQ forward-deployed engineers and data scientists are working within Purina’s technology environment to explore how NIQ consumer and market intelligence can support everyday AI-enabled workstreams and help teams access relevant insights more efficiently. "Understanding the needs of pet owners requires a clear view of how consumer behaviors, shopping habits, and category trends are evolving,” said Brian Donovan, Strategy and Insights, Purina. “Purina is working with NIQ to explore how its trusted intelligence can be incorporated into Purina’s everyday, AI-enabled workstreams, helping our team

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin6.8.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress disorder (PTSD). The trial, titled "Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression," or PIVOT, reflects VA’s commitment to pursuing innovative solutions for veterans who have not responded to existing treatments. Compass will donate the study drug - COMP360, a synthetic, proprietary pharmaceutical-grade formulation of psilocybin optimized for stability and purity. Compass will support the education and training of the investigators and their training team through the provision of training

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye